Suggested remit - To appraise the clinical and cost effectiveness of venetoclax in combination with bortezomib and dexamethasone within its marketing authorisation for treating relapsed or refractory multiple myeloma.
The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565. We have recently invited stakeholders to respond to a written consultation on the draft scope. On receiving updated regulatory timing information from the company that is developing venetoclax with bortezomib and dexamethasone, NICE has agreed that holding a scoping exercise at this time would not be appropriate. Consequently the consultation on the draft scope will be closed. The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause.
 
Status Discontinued
Process STA 2018
ID number 1565

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
08 May 2019 - 06 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 May 2019 Discontinued. The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565. We have recently invited stakeholders to respond to a written consultation on the draft scope. On receiving updated regulatory timing information from the company that is developing venetoclax with bortezomib and dexamethasone, NICE has agreed that holding a scoping exercise at this time would not be appropriate. Consequently the consultation on the draft scope will be closed. The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance